44,067 Shares in Zenas BioPharma, Inc. (NASDAQ:ZBIO) Acquired by Jefferies Financial Group Inc.

Key Points

• Jefferies Financial Group Inc. acquired 44,067 shares of Zenas BioPharma, valued at approximately $348,000, during the first quarter.
• Zenas BioPharma's stock experienced a decline of 1.1%, trading at $14.63, with a fifty-two week low of $5.83 and a high of $26.25.
• Analysts have set new price targets for ZBIO, with Wedbush issuing a $35.00 target and HC Wainwright setting a target of $30.00.

Jefferies Financial Group Inc. acquired a new position in Zenas BioPharma, Inc. (NASDAQ:ZBIO - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 44,067 shares of the company's stock, valued at approximately $348,000. Jefferies Financial Group Inc. owned 0.11% of Zenas BioPharma at the end of the most recent reporting period.

Separately, New York State Common Retirement Fund purchased a new stake in Zenas BioPharma in the first quarter worth about $49,000.

Analyst Ratings Changes

Several brokerages have commented on ZBIO. Wedbush restated an "outperform" rating and issued a $35.00 price objective on shares of Zenas BioPharma in a report on Thursday, May 15th. HC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of Zenas BioPharma in a report on Friday, May 16th.

Zenas BioPharma Stock Performance

Shares of ZBIO stock traded down $0.17 during trading hours on Friday, hitting $14.63. 84,361 shares of the company's stock traded hands, compared to its average volume of 146,164. The stock has a fifty day moving average price of $12.11. Zenas BioPharma, Inc. has a 12-month low of $5.83 and a 12-month high of $26.25. The firm has a market cap of $612.03 million and a PE ratio of -4.12.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.35. The business had revenue of $10.00 million for the quarter, compared to analysts' expectations of $5.00 million.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.